Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

Abstract

There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Med-iterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases as-sociated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to thenormalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately,the patients responded to tocilizumab re-treatment. This led us to conclude that physicians shouldnot stop the treatment, even in patients with normalized proteinuria levels.